Investing.comDoubao · 实盘不做把握 7/10不做原因:证据不足
北京时间·🕒 发布 04:08:33·⟳ 抓取 04:09:01 +28s·⚡ 决策 10-09 04:09:46 +45s·18.7 天前
AbCellera宣布将于10月22日公布更年期在研抗体ABCL635的1/2期数据，当前仅是演讲预告、未披露任何数据
消息本质是临床数据公布的日程预告，未包含任何可重定价的疗效/安全性结果，无新增基本面事实，距真正催化还有14天，现在不具备可交易edge。
📄 原文Investing.com↗ 原文
AbCellera to present phase 1/2 data on menopause drug candidate
By Investing.com Advertisement Advertisement AbCellera to present phase 1/2 data on menopause drug candidate Company Ne…
不做 AbCellera Biologics Inc.（ABCL.US）
仅为14天后临床数据公布的日程预告，无任何数据增量，方向与edge均无法确立；美股已收盘，真正催化在10月22日，届时依据实际读数再评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
AbCellera仅预告10月22日将披露更年期药物ABCL635的1/2期数据，没有任何实际读数。没有可判断方向的数据增量，当前不做，待数据公布前后再评估。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- 本条不含任何临床数值，无法形成多空方向的预期差，缺乏入场依据
主要风险
- 会前资金可能提前炒作导致波动，但属投机性押注而非本事件可支撑的edge
先例如何影响了这次决策
对本次决策的影响:因缺乏数据增量与对齐先例，支持当前AVOID，将研判推迟到10月22日实际数据公布
方向:无对齐先例；本条为无数据的演讲预告，先例统计无法在数据真空下给出方向
涨幅量级:不足，无真实读数可供校准幅度
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`abcellera abcl635 phase 1/2 menopause poster presentation october 22 2026 | abcellera vasomotor symptoms nk3r antibody data the menopause society 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不
原文全文
展开原文 · 7,343 字
AbCellera to present phase 1/2 data on menopause drug candidate By Investing.com
Advertisement
Advertisement
AbCellera to present phase 1/2 data on menopause drug candidate
Company News
Published
Oct 08, 2026, 04:08 PM
AbCellera to present phase 1/2 data on menopause drug candidate
View all comments (0)
0
AbCellera to present phase 1/2 data on menopause drug candidate
View all comments (0)
0
© Reuters
In this article:
ABCL
-6.31%
VANCOUVER, British Columbia - AbCellera Biologics Inc. (
NASDAQ:ABCL
) announced a poster presentation scheduled for October 22 at The Menopause Society’s 2026 Annual Meeting in San Diego, according to a press release statement.
The presentation will include safety, pharmacokinetics, pharmacodynamics, and efficacy data from the company’s Phase 1/2 trial of ABCL635, an investigational antibody drug for treating moderate-to-severe vasomotor symptoms associated with menopause. The data encompasses new safety results from the Phase 1 multiple ascending dose study and patient-reported outcome data from the Phase 2 study.
ABCL635 is designed as a non-hormonal, long-acting treatment targeting NK3R, a transmembrane protein on hypothalamic KNDy neurons involved in body temperature regulation. The drug candidate represents AbCellera’s first program from its GPCR and ion channel platform to reach clinical trials.
The Phase 2 trial is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of ABCL635 in postmenopausal women with moderate-to-severe vasomotor symptoms.
Vasomotor symptoms, which include hot flashes and night sweats, affect up to 80% of women during menopause. The company estimates approximately 12 million women in the U.S. experience moderate-to-severe symptoms, with more than six million seeking treatment.
The poster presentation is scheduled for Thursday, October 22 from 6:15 p.m. to 7:15 p.m. PDT at the Hilton Bayfront’s Indigo Exhibit Hall.
AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
AbCellera to present phase 1/2 data on menopause drug candidate
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,273.40
+94.2
+0.18%
US 500
7,769.90
-31.8
-0.41%
Dow Jones
51,231.70
+51.83
+0.10%
S&P 500
7,764.51
-37.26
-0.48%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.45
+0.37
+2.45%
Dollar Index
101.868
-0.062
-0.06%
Crude Oil WTI Futures
90.84
-0.65
-0.71%
Brent Oil Futures
103.49
-0.79
-0.76%
Natural Gas Futures
3.128
-0.042
-1.32%
Gold Futures
4,158.97
+1.97
+0.05%
Silver Futures
59.423
+0.002
0.00%
Copper Futures
6.5635
-0.0065
-0.10%
US Soybeans Futures
1,286.50
-11.00
-0.85%
U.S. 10Y
5.223
-0.055
-1.04%
U.S. 30Y
5.604
-0.057
-1.01%
U.S. 5Y
4.989
-0.032
-0.64%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.72
+0.23
+0.22%
Euro Bund Futures
121.20
+0.52
+0.44%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Oil cuts gains after Trump says will not attack Iran before U.S. midterm elections
By Investing.co
...
Oct 08, 2026
Nasdaq falls 1% on report OpenAI’s annualized revenue less than previously shown
By Investing.co
...
Oct 08, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SNDK
1,609.46
-4.90%
8.97M
AMD
620.79
-3.88%
19.85M
INTC
107.13
-5.30%
104.63M
SPCX
160.57
-4.19%
65.12M
AAPL
340.42
+1.11%
30.25M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.42M
GDDY
103.20
+6.16%
1.61M
CMG
32.65
+6.11%
63.69M
ACN
208.45
+6.00%
7.42M
IT
195.54
+5.26%
721.05K
CTSH
60.02
+5.17%
7.46M
EPAM
113.85
+5.11%
438.12K
Name
Last
Chg. %
Vol.
ALAB
346.90
-9.25%
5.28M
CRWV
81.58
-7.77%
41.30M
NBIS
219.71
-7.35%
21.10M
ARM
275.29
-6.48%
5.52M
GLW
152.84
-6.38%
7.94M
VST
156.18
-6.32%
10.58M
LITE
1,048.61
-5.62%
4.53M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SPCX
160.57
-4.19%
65.12M
APLD
23.850
+0.17%
54.59M
SNDK
1,609.46
-4.90%
8.97M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
AbCellera to present phase 1/2 data on menopause drug candidate
Company News
Published
Oct 08, 2026, 04:08 PM
AbCellera to present phase 1/2 data on menopause drug candidate
View all comments (0)
0
AbCellera to present phase 1/2 data on menopause drug candidate
View all comments (0)
0
© Reuters
In this article:
ABCL
-6.31%
VANCOUVER, British Columbia - AbCellera Biologics Inc. (
NASDAQ:ABCL
) announced a poster presentation scheduled for October 22 at The Menopause Society’s 2026 Annual Meeting in San Diego, according to a press release statement.
The presentation will include safety, pharmacokinetics, pharmacodynamics, and efficacy data from the company’s Phase 1/2 trial of ABCL635, an investigational antibody drug for treating moderate-to-severe vasomotor symptoms associated with menopause. The data encompasses new safety results from the Phase 1 multiple ascending dose study and patient-reported outcome data from the Phase 2 study.
ABCL635 is designed as a non-hormonal, long-acting treatment targeting NK3R, a transmembrane protein on hypothalamic KNDy neurons involved in body temperature regulation. The drug candidate represents AbCellera’s first program from its GPCR and ion channel platform to reach clinical trials.
The Phase 2 trial is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of ABCL635 in postmenopausal women with moderate-to-severe vasomotor symptoms.
Vasomotor symptoms, which include hot flashes and night sweats, affect up to 80% of women during menopause. The company estimates approximately 12 million women in the U.S. experience moderate-to-severe symptoms, with more than six million seeking treatment.
The poster presentation is scheduled for Thursday, October 22 from 6:15 p.m. to 7:15 p.m. PDT at the Hilton Bayfront’s Indigo Exhibit Hall.
AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
AbCellera to present phase 1/2 data on menopause drug candidate
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,273.40
+94.2
+0.18%
US 500
7,769.90
-31.8
-0.41%
Dow Jones
51,231.70
+51.83
+0.10%
S&P 500
7,764.51
-37.26
-0.48%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.45
+0.37
+2.45%
Dollar Index
101.868
-0.062
-0.06%
Crude Oil WTI Futures
90.84
-0.65
-0.71%
Brent Oil Futures
103.49
-0.79
-0.76%
Natural Gas Futures
3.128
-0.042
-1.32%
Gold Futures
4,158.97
+1.97
+0.05%
Silver Futures
59.423
+0.002
0.00%
Copper Futures
6.5635
-0.0065
-0.10%
US Soybeans Futures
1,286.50
-11.00
-0.85%
U.S. 10Y
5.223
-0.055
-1.04%
U.S. 30Y
5.604
-0.057
-1.01%
U.S. 5Y
4.989
-0.032
-0.64%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.72
+0.23
+0.22%
Euro Bund Futures
121.20
+0.52
+0.44%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Oil cuts gains after Trump says will not attack Iran before U.S. midterm elections
By Investing.co
...
Oct 08, 2026
Nasdaq falls 1% on report OpenAI’s annualized revenue less than previously shown
By Investing.co
...
Oct 08, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SNDK
1,609.46
-4.90%
8.97M
AMD
620.79
-3.88%
19.85M
INTC
107.13
-5.30%
104.63M
SPCX
160.57
-4.19%
65.12M
AAPL
340.42
+1.11%
30.25M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.42M
GDDY
103.20
+6.16%
1.61M
CMG
32.65
+6.11%
63.69M
ACN
208.45
+6.00%
7.42M
IT
195.54
+5.26%
721.05K
CTSH
60.02
+5.17%
7.46M
EPAM
113.85
+5.11%
438.12K
Name
Last
Chg. %
Vol.
ALAB
346.90
-9.25%
5.28M
CRWV
81.58
-7.77%
41.30M
NBIS
219.71
-7.35%
21.10M
ARM
275.29
-6.48%
5.52M
GLW
152.84
-6.38%
7.94M
VST
156.18
-6.32%
10.58M
LITE
1,048.61
-5.62%
4.53M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SPCX
160.57
-4.19%
65.12M
APLD
23.850
+0.17%
54.59M
SNDK
1,609.46
-4.90%
8.97M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
fe53c172fc· 2026-10-09 04:09 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前